Strongbridge Biopharma plc Announces Publication of Diabetes Subgroup Analysis from Phase 3 ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Strongbridge Biopharma plc Announces Publication of Diabetes Subgroup Analysis from Phase 3 ... Strongbridge Biopharma plcApril 7, 2021 GMT RECORLEV® (levoketoconazole) Treatment Demonstrates Clinically Meaningful Improvements in Cortisol Control and Clinical Benefit in Patients with Cushing’s Syndrome and Comorbid Diabetes Mellitus DUBLIN, Ireland and TREVOSE, Pa., April 07, 2021 (GLOBE NEWSWIRE) ...
Source: apnews.com